Pulmaquin Looks Promising for Treating Lung Infections in Non-CF Bronchiectasis Patients
empr.com
Aradigm has announced top-line results from two Phase 3 clinical trials of Pulmaquin (inhaled ciprofloxacin) for the treatment of patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic lung infections with Pseudomonas aeruginosa.